ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.

As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $39 price ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

A multi-omics study reveals that impaired branched-chain amino acid (BCAA) catabolism is a key driver of sarcopenia, suggesting it as a potential therapeutic target.

Today’s burning question from Cochlear's (ASX:COH) poorly received interim results is whether users are on a buyer’s strike ahead of upgraded implants and processors – or whether the problems are more ...